LEP and breast cancer: The increased susceptibility of ER+ BC compared with ER- BC to the negative impact of PEG-LPrA2 leptin-signaling inhibition could partially be related to differential mechanisms for leptin regulation of VEGF/VEGFR2 in the BC cells used.